138 related articles for article (PubMed ID: 38649657)
1. Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model.
Qi Y; Chan ML; Mould DR; Larimore K; Fisheleva E; Cherukuri A; Day J; Savarirayan R; Irving M; Bacino CA; Hoover-Fong J; Ozono K; Mohnike K; Wilcox WR; Bober MB; Henshaw J
Clin Pharmacokinet; 2024 May; 63(5):707-719. PubMed ID: 38649657
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia.
Chan ML; Qi Y; Larimore K; Cherukuri A; Seid L; Jayaram K; Jeha G; Fisheleva E; Day J; Huntsman-Labed A; Savarirayan R; Irving M; Bacino CA; Hoover-Fong J; Ozono K; Mohnike K; Wilcox WR; Horton WA; Henshaw J
Clin Pharmacokinet; 2022 Feb; 61(2):263-280. PubMed ID: 34431071
[TBL] [Abstract][Full Text] [Related]
3. C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia.
Savarirayan R; Irving M; Bacino CA; Bostwick B; Charrow J; Cormier-Daire V; Le Quan Sang KH; Dickson P; Harmatz P; Phillips J; Owen N; Cherukuri A; Jayaram K; Jeha GS; Larimore K; Chan ML; Huntsman Labed A; Day J; Hoover-Fong J
N Engl J Med; 2019 Jul; 381(1):25-35. PubMed ID: 31269546
[TBL] [Abstract][Full Text] [Related]
4. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial.
Savarirayan R; Tofts L; Irving M; Wilcox W; Bacino CA; Hoover-Fong J; Ullot Font R; Harmatz P; Rutsch F; Bober MB; Polgreen LE; Ginebreda I; Mohnike K; Charrow J; Hoernschemeyer D; Ozono K; Alanay Y; Arundel P; Kagami S; Yasui N; White KK; Saal HM; Leiva-Gea A; Luna-González F; Mochizuki H; Basel D; Porco DM; Jayaram K; Fisheleva E; Huntsman-Labed A; Day J
Lancet; 2020 Sep; 396(10252):684-692. PubMed ID: 32891212
[TBL] [Abstract][Full Text] [Related]
5. Vosoritide: First Approval.
Duggan S
Drugs; 2021 Nov; 81(17):2057-2062. PubMed ID: 34694597
[TBL] [Abstract][Full Text] [Related]
6. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial.
Savarirayan R; Wilcox WR; Harmatz P; Phillips J; Polgreen LE; Tofts L; Ozono K; Arundel P; Irving M; Bacino CA; Basel D; Bober MB; Charrow J; Mochizuki H; Kotani Y; Saal HM; Army C; Jeha G; Qi Y; Han L; Fisheleva E; Huntsman-Labed A; Day J
Lancet Child Adolesc Health; 2024 Jan; 8(1):40-50. PubMed ID: 37984383
[TBL] [Abstract][Full Text] [Related]
7. A long-acting C-natriuretic peptide for achondroplasia.
Schneider EL; Carreras CW; Reid R; Ashley GW; Santi DV
Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2201067119. PubMed ID: 35858423
[TBL] [Abstract][Full Text] [Related]
8. Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery.
Savarirayan R; Irving M; Maixner W; Thompson D; Offiah AC; Connolly DJ; Raghavan A; Powell J; Kronhardt M; Jeha G; Ghani S; Fisheleva E; Day JR
Sci Prog; 2021; 104(1):368504211003782. PubMed ID: 33761804
[TBL] [Abstract][Full Text] [Related]
9. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study.
Savarirayan R; Tofts L; Irving M; Wilcox WR; Bacino CA; Hoover-Fong J; Font RU; Harmatz P; Rutsch F; Bober MB; Polgreen LE; Ginebreda I; Mohnike K; Charrow J; Hoernschemeyer D; Ozono K; Alanay Y; Arundel P; Kotani Y; Yasui N; White KK; Saal HM; Leiva-Gea A; Luna-González F; Mochizuki H; Basel D; Porco DM; Jayaram K; Fisheleva E; Huntsman-Labed A; Day JRS
Genet Med; 2021 Dec; 23(12):2443-2447. PubMed ID: 34341520
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of vosoritide in the treatment of achondroplasia.
Paton DM
Drugs Today (Barc); 2022 Sep; 58(9):451-456. PubMed ID: 36102905
[TBL] [Abstract][Full Text] [Related]
11. Literature review and expert opinion on the impact of achondroplasia on medical complications and health-related quality of life and expectations for long-term impact of vosoritide: a modified Delphi study.
Savarirayan R; Baratela W; Butt T; Cormier-Daire V; Irving M; Miller BS; Mohnike K; Ozono K; Rosenfeld R; Selicorni A; Thompson D; White KK; Wright M; Fredwall SO
Orphanet J Rare Dis; 2022 Jun; 17(1):224. PubMed ID: 35698202
[TBL] [Abstract][Full Text] [Related]
12. Parents' Experience of Administering Vosoritide: A Daily Injectable for Children with Achondroplasia.
NiMhurchadha S; Butler K; Argent R; Palm K; Baujat G; Cormier-Daire V; Mohnike K
Adv Ther; 2023 May; 40(5):2457-2470. PubMed ID: 37017912
[TBL] [Abstract][Full Text] [Related]
13. Vosoritide Therapy in Children with Achondroplasia: Early Experience and Practical Considerations for Clinical Practice.
Semler O; Cormier-Daire V; Lausch E; Bober MB; Carroll R; Sousa SB; Deyle D; Faden M; Hartmann G; Huser AJ; Legare JM; Mohnike K; Rohrer TR; Rutsch F; Smith P; Travessa AM; Verardo A; White KK; Wilcox WR; Hoover-Fong J
Adv Ther; 2024 Jan; 41(1):198-214. PubMed ID: 37882884
[TBL] [Abstract][Full Text] [Related]
14. Evidence of feedback regulation of C-type natriuretic peptide during Vosoritide therapy in Achondroplasia.
Prickett TCR; Espiner EA; Irving M; Bacino C; Phillips JA; Savarirayan R; Day JRS; Fisheleva E; Larimore K; Chan ML; Jeha GS
Sci Rep; 2021 Dec; 11(1):24278. PubMed ID: 34930956
[TBL] [Abstract][Full Text] [Related]
15. Vosoritide treatment for children with hypochondroplasia: a phase 2 trial.
Dauber A; Zhang A; Kanakatti Shankar R; Boucher K; McCarthy T; Shafaei N; Seaforth R; Castro MG; Dham N; Merchant N
EClinicalMedicine; 2024 May; 71():102591. PubMed ID: 38813446
[TBL] [Abstract][Full Text] [Related]
16. Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C.
Brennan BJ; Lemenuel-Diot A; Snoeck E; McKenna M; Solsky J; Wat C; Mallalieu NL
Br J Clin Pharmacol; 2016 Apr; 81(4):658-66. PubMed ID: 26529640
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.
Chandasana H; Thapar M; Hayes S; Baker M; Gibb DM; Turkova A; Ford D; Ruel T; Wiznia A; Fairlie L; Bwakura-Dangarembizi M; Mujuru H; Alvero C; Farhad M; Hazra R; Townley E; Buchanan A; Bollen P; Waalewijn H; Colbers A; Burger D; Acosta EP; Singh R;
Clin Pharmacokinet; 2023 Oct; 62(10):1445-1459. PubMed ID: 37603217
[TBL] [Abstract][Full Text] [Related]
18. [New treatments for achondroplasia may be efficacious in other forms of short stature].
Nilsson O
Lakartidningen; 2021 Feb; 118():. PubMed ID: 33647161
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing.
Passarell J; Jaworowicz D; Ludwig E; Rabinovich-Guilatt L; Cox DS; Levi M; Garin M; Fiedler-Kelly J; Bond M
J Clin Pharmacol; 2020 Aug; 60(8):1039-1050. PubMed ID: 32333684
[TBL] [Abstract][Full Text] [Related]
20. TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias.
Breinholt VM; Rasmussen CE; Mygind PH; Kjelgaard-Hansen M; Faltinger F; Bernhard A; Zettler J; Hersel U
J Pharmacol Exp Ther; 2019 Sep; 370(3):459-471. PubMed ID: 31235532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
